Karyopharm to Report Third Quarter 2016 Financial Results on November 7, 2016

NEWTON, Mass., Oct. 31, 2016 -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report third quarter 2016 financial results and provide a company update on Monday, November 7, 2016. Karyopharm's management team will host a conference call and audio webcast at 5:00 p.m. ET on Monday, November 7, 2016 to discuss the financial results and recent business developments.

To access the conference call, please dial (855) 437-4406 (local) or (484) 756-4292 (international) at least five minutes prior to the start time and refer to conference ID 96721150. A live audio webcast of the call will be available under "Events & Presentations" in the Investor section of the Company's website, investors.karyopharm.com/events.cfm. An archived webcast will be available on the Company's website approximately two hours after the event.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. Karyopharm's SINE™ compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). The Company's initial focus is on seeking regulatory approval and commercialization of its lead drug candidate, oral selinexor (KPT-330). To date, over 1,700 patients have been treated with selinexor and it is currently being evaluated in several mid- and later-phase clinical trials across multiple cancer indications, including multiple myeloma in combination with low-dose dexamethasone (STORM) and backbone therapies (STOMP), and in acute myeloid leukemia (SOPRA), diffuse large B-cell lymphoma (SADAL), and liposarcoma (SEAL), among others.  Karyopharm plans to initiate a pivotal randomized Phase 3 study of selinexor in combination with bortezomib (Velcade®) and low-dose dexamethasone (BOSTON) in patients with multiple myeloma in early 2017.  In addition to single-agent and combination activity against a variety of human cancers, SINE™ compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm, which was founded by Dr. Sharon Shacham, currently has five investigational programs in clinical or preclinical development. For more information, please visit www.karyopharm.com.

Contact:

Justin Renz
(617) 658-0574
[email protected]

Gina Nugent
(617) 460-3579
[email protected]